FDA Approves FORZINITY (Elamipretide / SS-31): The First Mitochondria-Targeted Drug in History
19 September 2025: FDA granted accelerated approval to FORZINITY (elamipretide, SS-31) for Barth syndrome. Analysis of TAZPOWER, ReCLAIM-2.
On 19 September 2025, the US Food and Drug Administration granted accelerated approval to FORZINITY (elamipretide hydrochloride) for Barth syndrome. The decision does more than provide a first therapy for an ultra-rare X-linked disorder. It marks the first FDA approval of a mitochondria-targeted peptide in the history of drug development. For mitochondrial medicine, SS-31 has moved from an experimental concept to a regulatory precedent.
The key facts at a glance
Approval date: 19 September 2025 (FDA Accelerated Approval) Brand name: FORZINITY (elamipretide hydrochloride) Indication: Barth syndrome in patients with a body weight of at least 30 kg Dose: 40 mg subcutaneously once daily Evidence base: TAZPOWER Phase 2 RCT plus 168-week open-label extension (Thompson et al. 2024, Genet Med, PMID 38602181) Manufacturer: Stealth BioTherapeutics Historic: First FDA-approved mitochondria-targeted peptide
Mitochondria-targeted tetrapeptide (Elamipretide) that stabilizes cardiolipin and prevents ROS formation at the source.
What FORZINITY Is
FORZINITY is the trade name for elamipretide hydrochloride, a synthetic tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2. The molecule is better known in the research community under its academic names SS-31, MTP-131 and Bendavia. It was originally developed in the laboratory of Hazel Szeto and Peter Schiller more than two decades ago as part of a class of mitochondria-targeted "SS peptides" (Szeto-Schiller peptides).
The core property of elamipretide is a specific, non-catalytic binding to cardiolipin, a phospholipid that is found almost exclusively on the inner mitochondrial membrane and that structures the cristae. By interacting with cardiolipin, SS-31 supports the spatial organisation of the respiratory chain complexes, stabilises cristae architecture and reduces electron leakage. The result is better oxidative phosphorylation in dysfunctional mitochondria without measurable effects on healthy organelles.
Why This Is Historic
Mitochondrial medicine has been a field of great expectations and regulatory disappointments for decades. Coenzyme Q10 analogues, idebenone, EPI-743 and other candidates have been investigated in clinical trials, but none have received a US marketing authorisation as a mitochondria-targeted therapy in the narrow sense. FORZINITY is the first drug whose stated mechanism of action, cardiolipin stabilisation at the inner mitochondrial membrane, is the reason for its approval.
For research on peptides such as SS-31, MOTS-c, humanin and other mitochondrial modulators, this is a regulatory validation of the underlying research programme. The FDA did not classify elamipretide as a classical replacement therapy like enzyme substitution, but as a small molecule that directly addresses mitochondrial membrane physiology. This creates a template that other developers of mitochondrial peptides can now reference.
At the same time, the approval is precisely limited. It applies to patients with Barth syndrome who weigh at least 30 kg. It was granted under the Accelerated Approval pathway, based on a change in a surrogate endpoint (knee extensor muscle strength). Full confirmation via a post-marketing study is still pending and is planned from the first half of 2026.
The Evidence Base: TAZPOWER
Phase 2 RCT plus 168-week open-label extension
The approval of FORZINITY is based primarily on the TAZPOWER programme. TAZPOWER began as a Phase 2 randomised, double-blind, placebo-controlled crossover study in genetically confirmed Barth syndrome. Patients received 40 mg elamipretide subcutaneously once daily or placebo. After the crossover phase, eligible patients entered an open-label extension (OLE) that reached 168 weeks of continuous exposure.
The data that formed the basis for the 2025 approval were published in Genetics in Medicine by Thompson et al. in 2024 (PMID 38602181). The authors report durable improvements in motor function, cardiac geometry and the cardiolipin biomarker profile over 168 weeks of treatment.
TAZPOWER OLE, 168 weeks, Thompson 2024
- Six-minute walk test: Cumulative improvement of 96.1 metres from OLE baseline (p = 0.003)
- Muscle strength: Improvement in knee extensor strength (basis for the approved indication)
- Cardiac remodelling: Clinically meaningful improvements in left ventricular end-diastolic and end-systolic volumes and in stroke volume
- Cardiolipin biomarker: Significant decrease in the MLCL:CL ratio, which is pathognomonic for Barth syndrome
- Safety: Injection site reactions were the most common adverse event. No serious drug-related events.
A preclinical parallel track supports these clinical signals. In 2024, a study in Scientific Reports demonstrated that SS-31 improves cardiac mitophagy in a Barth mouse model (Nature Scientific Reports, doi 10.1038/s41598-024-64368-y). A 2025 comprehensive mechanism review in the International Journal of Molecular Sciences (PMC11816484) summarises the current understanding of SS-31/MTP-131/Bendavia as a cardiolipin-selective membrane stabiliser.
What Barth Syndrome Is
Barth syndrome is an ultra-rare, X-linked mitochondrial disorder that affects roughly 150 known patients in the United States and an estimated 250 to 300 worldwide. It is caused by loss-of-function mutations in the TAFAZZIN gene (TAZ), which encodes a transacylase that remodels immature cardiolipin into the mature, tetralinoleoyl-enriched form.
The consequences are structural and functional. Without mature cardiolipin, the inner mitochondrial membrane cannot fully organise its respiratory chain supercomplexes and cristae. Monolysocardiolipin (MLCL) accumulates, and the MLCL:CL ratio rises. Clinically, patients present with childhood-onset cardiomyopathy, skeletal muscle weakness, cyclic neutropenia with recurrent infections and growth delay. Until 2025, supportive care was the only treatment option.
The mechanistic logic of SS-31 in this disease is therefore direct. Where cardiolipin remodelling fails, a molecule that binds cardiolipin and stabilises its electrostatic and structural role becomes a rational therapeutic target.
The Other Clinical Programmes
Elamipretide has been tested in several other indications besides Barth syndrome. Not all of these programmes met their primary endpoints, and the overall picture is more mixed than the FORZINITY headline suggests.
ReCLAIM-2 in dry AMD, honestly read
The ReCLAIM-2 Phase 2 study (Ehlers et al. 2024, Ophthalmol Sci, PMID 39605874) evaluated subcutaneous elamipretide in geographic atrophy secondary to dry age-related macular degeneration. The primary endpoints, change in low-luminance best-corrected visual acuity and GA lesion growth rate, were not met.
What ReCLAIM-2 did show was a secondary imaging signal. Patients on elamipretide had a 43% reduction in ellipsoid zone attenuation, a photoreceptor integrity marker, compared with placebo (p = 0.003). This signal supported continuation into the Phase 3 ReNEW and ReGAIN programmes but should not be confused with a positive trial. Honest framing matters: ReCLAIM-2 is a primary miss with a biologically plausible secondary signal, not proof of efficacy in AMD.
Primary mitochondrial myopathy
The pivotal MMPOWER-3 study in primary mitochondrial myopathy did not meet its primary endpoints either. A post-hoc analysis suggested that patients with nuclear DNA variants may respond, while those with mitochondrial DNA variants did not. This is a hypothesis-generating signal, not evidence, and is being re-examined in new trial designs.
Heart failure
The Phase 2 PROGRESS-HF study in heart failure with reduced ejection fraction did not show a significant improvement in left ventricular end-systolic volume at four weeks. Elamipretide was well tolerated, but the clinical signal was not robust.
Pipelines still on the board
New trials are expected in MELAS, Friedreich ataxia and various cardiomyopathy settings. The regulatory precedent created by FORZINITY is likely to accelerate these programmes, because it establishes cardiolipin stabilisation as a legitimate therapeutic axis.
What This Means for Peptide Research
For researchers working on mitochondria-targeted peptides, FORZINITY is a meaningful inflection point. The approval does not prove that SS-31 will work in every mitochondrial disease, and it does not extend to research-grade material used in laboratory settings. What it does is validate the research programme that has accumulated over the past two decades, from Szeto and Schiller's early cardiolipin work to the 2025 IJMS mechanism review.
Three implications follow. First, mechanism-based approval is possible for mitochondrial peptides, provided that a well-chosen disease and a well-chosen endpoint align with the molecular target. Second, cardiolipin is now an accepted drug target, which opens the door to both follow-on SS-peptides and other chemical classes that stabilise the inner mitochondrial membrane. Third, funding and trial design for mitochondrial indications are likely to shift, as the regulatory bar is no longer purely hypothetical.
Research-Grade SS-31 vs Pharmaceutical FORZINITY
The distinction is important and should not be blurred.
| Feature | FORZINITY (approved drug) | Research-grade SS-31 |
|---|---|---|
| Regulatory status | FDA-approved for Barth syndrome, at least 30 kg | For research use only (RUO) |
| Manufacturing | GMP, pharmaceutical quality | Research-grade |
| Intended use | Patients with Barth syndrome | In vitro and preclinical research |
| Access | Prescription only, via specialty pharmacy | Available to qualified researchers |
| Formulation | Standardised pharmaceutical injection | Lyophilised research peptide |
FORZINITY is the clinical product for a defined patient population. Research-grade SS-31 is the laboratory tool that made the clinical product possible and that will continue to be used to probe cardiolipin biology, mitochondrial membrane physiology and new indications.
Sourcing for laboratory research
When ordering SS-31 for research, the usual analytical quality criteria apply. Expect a meaningful Certificate of Analysis with HPLC purity, mass spectrometry identity confirmation, peptide content and residual moisture data. Independent third-party verification, for example by Janoshik Analytical, adds credibility. Storage: lyophilised at -20 degrees C, reconstituted solutions refrigerated at 2 to 8 degrees C and used promptly.
Outlook
The 2025 approval of FORZINITY is not the end of the SS-31 story but the regulatory beginning. The Phase 3 ReNEW programme in dry AMD is expected to read out in 2026, the ReGAIN study is being prepared, and the Barth post-marketing confirmatory study is planned from 2026 onwards. Parallel pipelines in MELAS, Friedreich ataxia and cardiomyopathy are being repositioned in the light of the Barth precedent.
For the research community, the message is straightforward. A mitochondria-targeted peptide has, for the first time in history, reached FDA approval. That fact alone rewrites what is possible for this class of molecules.
For laboratories and qualified researchers in the European Union, research-grade SS-31 remains available as a tool for in vitro and preclinical work. The pharmaceutical product FORZINITY and research-grade material serve different purposes and should never be conflated.
References
- US Food and Drug Administration. FORZINITY (elamipretide hydrochloride) injection, for subcutaneous use. Prescribing Information, 19 September 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000lbl.pdf
- Thompson WR, et al. TAZPOWER 168-week open-label extension in Barth syndrome. Genetics in Medicine, 2024. PMID 38602181.
- Ehlers JP, et al. ReCLAIM-2 Phase 2 in geographic atrophy secondary to dry AMD. Ophthalmology Science, 2024. PMID 39605874.
- Elamipretide mechanism comprehensive review. International Journal of Molecular Sciences, 2025. PMC11816484.
- SS-31 improves cardiac mitophagy in a Barth mouse model. Scientific Reports, 2024. doi 10.1038/s41598-024-64368-y.
- Contemporary insights into mitochondria-targeted peptide therapeutics. 2024/2025. PMC12164653.